Related references
Note: Only part of the references are listed.Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Hester van Cruijsen, Astrid van der Veldt, Klaas Hoekman
Hester van Cruijsen et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
A. A. M. van der Veldt et al.
BRITISH JOURNAL OF CANCER (2008)
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib
Doru T. Alexandrescu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors
M. M. Cooney et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Betty Y. Y. Tam et al.
NATURE MEDICINE (2006)
Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase
ZG Jin et al.
CIRCULATION RESEARCH (2003)
Share Paper
